Catalyst Event
Johnson & Johnson (JNJ) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/18/2026, 12:00:00 AM
Importance is Medium as FDA approval of a first-in-class drug typically has a significant impact on valuation. The U.S. FDA approved ICOTYDE™ (icotrokinra) on March 18, 2026, which analysts forecast to be a major growth driver, forecasted
Korean Translation
신약 승인은 기업 가치에 유의미한 영향을 미치므로 중요도를 Medium으로 산정함. 2026년 3월 18일, 미국 FDA가 ICOTYDE™(icotrokinra)를 승인하였으며, 이는 분석가들에 의해 주요 성장 동력이 될 것으로 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.
5/24/2026, 12:00:00 AM
Exelixis Inc (EXEL) · Earnings Release
Exelixis is expected to report its Q1 2026 earnings on or around May 12, 2026, and analysts forecast EPS of approximately $0.73-$0.76; high importance reflects potential volatility from earnings surprises, forecasted and scheduled.
5/12/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol Myers Squibb Q1 2026 results conference call is scheduled for 2026-04-30; as the next earnings catalyst following the strong Q4 2025 outlook, a multi-percent share move is reasonably expected based on typical earnings volatility scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva is scheduled to release its financial results for the first quarter of 2026 before the market opens on April 29, 2026, followed by a conference call with management; a 5% price impact is estimated for this earnings release, scheduled.
4/29/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
First quarter 2026 earnings release; importance is estimated as Medium because quarterly earnings reports often result in price movements exceeding 5%, scheduled.
4/24/2026, 12:00:00 AM